CD38

Assets acting on this target.

Class
Anti-CD38 monoclonal antibody
Pathway
Plasma cell / B-cell depletion

CD38 is a protein found in high amounts on the surface of plasma cells, the antibody-producing cells that, when malignant, cause multiple myeloma. CD38 is also expressed at lower levels on other immune cells and functions as an enzyme involved in calcium-related cell signaling. Antibodies directed against CD38 bind these cells and recruit the immune system's own destruction mechanisms, along with promoting direct cell death, to eliminate CD38-bearing cells. This makes the target relevant not only in multiple myeloma but potentially in other conditions driven by abnormal or excessive antibody-producing cells, since removing the source of unwanted antibodies can quiet disease activity. Beyond naked antibodies, CD38 is also being explored as an anchor point for delivering attached cytotoxic drugs or radioactive isotopes directly to target cells, a strategy intended to increase potency in cases where antibody-recruited immune killing alone is insufficient. Because CD38 is expressed on some healthy cells in addition to diseased ones, its modulation carries mechanistic trade-offs, including effects on normal antibody production and on certain immune cell populations. Understanding CD38 biology explains both the broad appeal of this target across plasma-cell disorders and the rationale behind pursuing multiple antibody formats against it.

By indication

Related mechanisms

CD38 drugs compared

13 drugs, stage by indication
13 drugs acting on CD38: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
DaratumumabJohnson & Johnsonmonoclonal antibodyApprovedApproved in Multiple Myeloma; Phase 3 in AL Amyloidosis
IsatuximabSanofimonoclonal antibodyApprovedApproved in Multiple Myeloma
BCD-264Biocadmonoclonal antibody (biosimilar)Phase 3Phase 3 in Multiple Myeloma
CT-P44Celltrionmonoclonal antibody (proposed daratumumab biosimilar)Phase 3Phase 3 in Multiple Myeloma
FelzartamabBiogenmonoclonal antibodyPhase 3Phase 3 in IgA Nephropathy; Phase 3 in Multiple Myeloma; Phase 3 in Primary Membranous Nephropathy
HLX15Dr. Reddy's Laboratories, Shanghai Henlius Biotechmonoclonal antibody (anti-CD38 biosimilar candidate)Phase 3Phase 3 in Multiple Myeloma
LumrotatugKeymed Biosciences, Timberlyne Therapeuticsmonoclonal antibody (humanized, anti-CD38)Phase 3Phase 3 in Multiple Myeloma
MezagitamabTakeda Pharmaceutical Companymonoclonal antibody (anti-CD38)Phase 3Phase 3 in Chronic Kidney Disease; Phase 3 in IgA Nephropathy
QL2109Qilu Pharmaceuticalmonoclonal antibody (anti-CD38)Phase 3Phase 3 in Multiple Myeloma
SanritatugHangzhou Sumgen Biotech Co., Ltd.monoclonal antibodyPhase 3Phase 3 in Multiple Myeloma; Phase 2 in Systemic Lupus Erythematosus
SCTC21CSinocelltech Group Ltd.biologic (registry-typed, subtype undisclosed)Phase 3Phase 3 in AL Amyloidosis; Phase 3 in Multiple Myeloma; Phase 1/2 in IgA Nephropathy; Phase 1/2 in Systemic Lupus Erythematosus
CID-103CASI Pharmaceuticals, Inc.monoclonal antibody (fully human IgG1, anti-CD38)Phase 2Phase 2 in Immune Thrombocytopenia; Phase 1 in Multiple Myeloma
STI-6129ACEA Therapeutics, Sorrento Therapeutics, Inc.antibody-drug conjugate (ADC)Phase 1/2Phase 1/2 in Multiple Myeloma

← all mechanisms